H.C. Wainwright lowered the firm’s price target on SpringWorks Therapeutics to $52 from $58 and keeps a Buy rating on the shares. The analyst made model changes after SpringWorks announced the top-line results from the Phase 2b ReNeu trial.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SWTX:
- SpringWorks Therapeutics Announces Positive Topline Results from the Phase 2b ReNeu Trial of Mirdametinib in NF1-PN
- SpringWorks Therapeutics’ mirdametinib shows efficacy in Phase 2b NF1-PN trial
- SpringWorks Therapeutics price target lowered to $58 from $66 at H.C. Wainwright
- SpringWorks Therapeutics reports Q3 EPS ($1.27), consensus ($1.33)
- SpringWorks Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights